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Abstract
Background: Atrial fibrillation is a major public health problem and is the most common cardiac arrhythmia,
affecting an estimated 2.7 million Americans. The true prevalence of atrial fibrillation is likely underestimated
because episodes are often sporadic; therefore, it is challenging to detect and record an occurrence in a “real
world” setting. To date, mobile health tools that promote earlier detection and treatment of atrial fibrillation and
improvement in self-management behaviors and knowledge have not been evaluated. This study will be the first
to address the epidemic problem of atrial fibrillation with a novel approach utilizing advancements in mobile
health electrocardiogram technology to empower patients to actively engage in their healthcare and to evaluate
impact on quality of life and quality-adjusted life years. Furthermore, sending a daily electrocardiogram transmission,
coupled with receiving educational and motivational text messages aimed at promoting self-management and a
healthy lifestyle may improve the management of chronic cardiovascular conditions (e.g., hypertension, diabetes, heart
failure, etc.). Therefore, we are currently conducting a randomized controlled trial to assess the efficacy of a mobile
health intervention, iPhone® Helping Evaluate Atrial fibrillation Rhythm through Technology (iHEART) versus usual
cardiac care.
Methods: The iHEART study is a single center, prospective, randomized controlled trial. A total of 300
participants with a recent history of atrial fibrillation will be enrolled. Participants will be randomized 1:1 to
receive the iHEART intervention, receiving an iPhone® equipped with an AliveCor® Mobile ECG and accompanying
Kardia application and behavioral altering motivational text messages or usual cardiac care for 6 months.
Discussion: This will be the first study to investigate the utility of a mobile health intervention in a “real world” setting.
We will evaluate the ability of the iHEART intervention to improve the detection and treatment of recurrent atrial
fibrillation and assess the intervention's impact on improving clinical outcomes, quality of life, quality-adjusted life-years
and disease-specific knowledge.
Trial registration: NCT02731326; Verified April 2016
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Background
Atrial fibrillation (AF) is a major public health problem
and is the most common cardiac arrhythmia, affecting
an estimated 2.7 million Americans. By 2050, the num-
ber of Americans with AF will exceed 12 million [1–3].
This rise in AF is due to the advancing age of the popu-
lation and the number of individuals living with multiple
cardiovascular chronic conditions (e.g., heart failure,
hypertension, heart disease, diabetes) that are known to
be associated with the development of AF [4, 5]. The
true prevalence of AF is likely underestimated because
episodes are often sporadic; therefore, it is challenging
to detect and record an occurrence of AF in a “real
world” setting. In fact, AF recurrence is estimated to be
50 % in the first year after the initiation of treatments
that restore a normal heart rhythm, highlighting the
need for improved electrocardiogram (ECG) methods
for detecting AF [6].
The market for mobile health (mHealth) and afford-
able health technology continues to rapidly increase
worldwide. In fact, almost 28 % of the world’s population
own and use a smartphone, and this number is expected
to increase to approximately 50 % by 2018 [7]. While
current clinical guidelines advocate for AF screening, the
application of simple, acceptable, easy to use “real world”
approaches using mobile phones for ECG monitoring
that enable patients to self-manage and self-diagnose is
emerging.
To date, mHealth tools that promote earlier detec-
tion and treatment of AF, adherence to cardiovascular
regimens, and improvement in self-management be-
haviors and AF knowledge have not been evaluated.
Additionally, the impact of educational text messaging on
the self-management of AF-associated chronic cardiovascu-
lar conditions has not been investigated in an underserved,
primarily Latino population. Prior to 2012, mHealth
technology for capturing and sending ECG rhythms to
healthcare providers from a smartphone for rapid real-time
evaluation did not exist [8].
Utilizing recent developments of smartphone ECG
technology, the Evaluate Atrial fibrillation Rhythm
through Technology (iHEART) study is a randomized
controlled trial (RCT) that will assess the efficacy of an
mHealth intervention versus usual cardiac care. This
study will be the first to address the epidemic problem
of AF with a novel approach using advancements in
mHealth ECG technology to empower patients to ac-
tively engage in their healthcare. Detection and treat-
ment (e.g., medication adjustments, cardioversion) of AF
may be improved through more rapid patient-provider
communication facilitated by daily mHealth ECG moni-
toring. The impact of AF, chronic conditions, and pre-
scribed treatments on quality of life (QoL) and quality-
adjusted life-years (QALYs) will also be evaluated.
Furthermore, sending daily ECG transmissions coupled
with receiving educational and motivational text mes-
sages aimed at promoting self-management and a
healthy lifestyle may improve co-existing chronic cardio-
vascular conditions (e.g., hypertension, diabetes, heart
failure, etc.).
This article describes the study design and research
methods used to evaluate iHEART (Clinicaltrials.gov ID:
NCT02731326), a randomized controlled trial to deter-
mine whether participants receiving behavior altering
motivational text messages will demonstrate a greater
improvement in their cardiovascular measures (e.g.,
blood pressure, glucose levels) and AF knowledge from
baseline to 6 months as compared to those in the usual
care group. The primary hypothesis is that participants
utilizing the iHEART intervention are more likely to
have AF episodes detected and receive subsequent treat-
ment for recurrent AF earlier as compared to the usual
care group. The usual care group receives “guideline-di-
rected medical care” defined by the treating cardiologist
and the 2014 ACC/AHA/HRS guidelines [9]. Secondary
findings will examine whether participants in the
iHEART intervention will have a better self-reported




The iHEART study is a single-center, prospective,
RCT (Fig. 1). The primary aims of the iHEART study
are to: (1) document AF using real-time ECG capture;
(2) evaluate the impact on AF treatment and QALYs;
and (3) evaluate the effectiveness of text messaging
on AF knowledge and promoting proactive self-
management of multiple chronic conditions. Partici-
pants are randomized to one of two groups: iHEART
(intervention group) or usual care (control group). All
participants enrolled will be followed for a period of
6 months. This study protocol adheres to the appro-
priate standards of reporting as stated in the Standard
Protocol Items: Recommendations for Interventional
Trials statement and facilitates the methodology of
the Consolidated Standards of Reporting Trials state-
ment for later dissemination of the results of the out-
lined RCT [10, 11].
Study population
Patients will be screened for eligibility. Those who meet
inclusion criteria will be approached for enrollment after
the patient’s provider agrees to the study protocol and is
willing to receive and review ECG transmissions. The
details of the study will be explained in English or
Spanish, and patients will be given an opportunity to ask
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questions before signing informed consent. A copy of
the consent form will be given to the patient.
Inclusion criteria will include documented AF that has
been treated in the last 30 days resulting in the restoration
of normal sinus rhythm. The operational definition of AF
for this study will include the presence of AF captured by
the AliveCor® Mobile ECG, a standard 12 lead ECG, Holter,
or any other external recording mechanism that documents
AF. Over a six month period, those individuals with ≤ 7 days
of AF will be considered paroxysmal, and those with greater
than 7 days of continuous AF will be defined as persistent
AF per the AHA/ACC/HRS guidelines [9].
The main exclusion criteria for participants include
documented permanent (chronic) AF, unwillingness to
use technology and have one’s clinical data collected
over the study period, unwillingness to receive and read
cardiovascular text messaging three times a week, and
patients who have a documented medical history of cog-
nitive impairment. The complete list of inclusion and
exclusion criteria is provided in Table 1.
Data and safety monitoring
The study was approved by the Columbia University Med-
ical Center Institutional Review Board (IRB-AAAO2555).
Participants provided written informed consent prior to
enrollment and all data collection procedures are in
accordance with the Health Information Portability and
Accountability Act regulations.
Sample size and power
A total of 300 participants with documented AF who
are undergoing clinical treatment of their AF with
electrical cardioversion, radiofrequency ablation and/
or medical management to restore normal sinus
rhythm will be enrolled. After a normal rhythm is re-
stored, participants will be randomized to usual car-
diac care (n = 150) or usual cardiac care plus the
iHEART intervention (n = 150). The target sample size
and power was calculated based on the difference in
AF detection rates between the intervention group
and the control group. From the preliminary data,
Fig. 1 Flowchart for study procedures
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there were 4 episodes of AF during the follow-up of
12 patients, or a detection rate of 0.33 vs. a detection
rate of 8 % among controls. Using a Poisson regres-
sion with a two-sided test at a 95 % significance level
(α = .05), 80 % power was used to detect a relative
risk (RR) of less than 1.7 between the intervention
group and the control group. The population will be
recruited from the Columbia University Medical
Center (CUMC) cardiac services and will include
English and Spanish speaking participants.
Randomization
The randomization process will be performed by a ran-
dom computer number generator in a one-to-one block
allocation ratio. In order to achieve a balance of applic-
able participant characteristics in both the intervention
and control groups, participants will be stratified based
on age and gender. Specifically, when the sample size is
small, block randomization is commonly used in clinical
trials to reduce bias and achieve balance in the allocation
of participants to treatment arms. Block randomization
increases the probability that each treatment arm
contains an equal number of participants by sequencing
individuals by block [12].
Outcome assessments
Upon study entry, all relevant clinical data will be col-
lected at baseline and monthly throughout six months
via an electronic medical records system review. This
will be used to capture and quantify cardiac outcomes in
both groups. In addition, all outside medical records will
be requested, and participants will be contacted monthly
to capture any hospitalizations, cardiac events, or
changes in therapy that may occur outside of our center
and clinics. AF in the usual care group may be detected
during routine follow-ups with providers, as well as dur-
ing self-evaluations such as a pulse check initiated as a
result of participant-reported symptoms or changes in
health status. AF may also be captured by a 12-lead
ECG, pulse check, or heart sound auscultation during an
exam that reveals an irregular heart rhythm. Participants
in the usual care group may seek medical evaluation by
their providers because of a change in their health status
or symptoms (shortness of breath, palpitations, fatigue),
which may lead to further cardiac monitoring or testing
(e.g., echocardiogram) that may reveal AF. This could in-
clude Holter monitoring (24 h) or extended cardiac
monitoring (7–30 days) that may document AF and be
the basis for changes in treatments prescribed by their
providers (e.g., medication changes or dosage adjust-
ments, cardioversion). In the intervention group, Alive-
Cor® Mobile ECG transmissions will be read daily to
detect recurrence of AF or other arrhythmias. All results
and any treatment changes due to mobile ECG findings
will be recorded over the course of the study period.
All study participants will be asked to complete a
series of questionnaires including the Atrial Fibrillation
Knowledge Scale (AFKS), the Canadian Cardiovascular
Society Severity in Atrial Fibrillation scale (CCS-SAF),
the Atrial Fibrillation Effect on Quality of Life (AFEQT),
the Control Attitudes Scale-Revised (CAS-R), the Mor-
isky 4-item Self-Report Measure of Medication-Taking
Behavior (MMAS-4), the Self-Efficacy for Appropriate
Medication Use Scale (SEAMS), the Short Form Health
Survey (SF-36 Quality of Life), European Questionnaire
5 Dimensions (EQ-5D), the Patient Health Question-
naire (PHQ-9), and the State Trait Anxiety Inventory
(STAI). These measures will be administered to both the
intervention and control groups at baseline prior to any
procedures, such as a cardioversion or ablation, and
again at the 6-month follow-up visit for the purpose of
comparison. All questionnaires have been used in similar
cardiac populations and those diagnosed with/at risk for
the development of AF.
Study intervention
Participants randomized to the iHEART intervention
will receive an iPhone® and cellular service plan with
unlimited data/text messaging, the AliveCor® Mobile
ECG, and Behavioral Altering Motivational (BAM) text
messaging three times a week for six months. BAM is an
in-house database that automatically sends one-way text
messages to the intervention participant related to their
AF, as well as two underlying cardiovascular risk factors
of their choosing.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Males and females (English or Spanish speaking) age ≥ 18 years with
a prior history of AF in the last 30 days that was treated and normal
rhythm restored
• Already utilizes a smartphone prior to enrollment
• Ability to successfully use the AliveCor™ Heart Monitor, capture a
baseline ECG, and transmit on the day of enrollment
• Demonstrated ability to receive and read text messages on the day
of enrollment
• Willingness to complete the study questionnaires at baseline and 6 months
• Documented permanent (chronic) AF
• Unwillingness to have their clinical data collected over
the study period
• Unwillingness to receive and read cardiovascular text
messaging three times a week.
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AliveCor™ heart monitor
The AliveCor® Mobile ECG, an FDA-approved smart-
phone technology, works through a free application,
“Kardia.” It captures a highly sensitive (98 %), specific
(97 %), and accurate (97 %) single-lead ECG recording
through two electrodes on the back of the smartphone
[8]. When the application is opened, recording begins
automatically when both electrodes make contact with
skin (Fig. 2). Transmissions are automatically uploaded
to the study portal within the AliveCor® “cloud”. All par-
ticipants will receive in-person training on the use of the
study equipment at enrollment. A return demonstration
from the participant to the research coordinator will be
required at baseline enrollment. This will include how to
capture an ECG daily and in the setting of symptoms, as
well as how to record any associated symptoms in the
application.
All ECG images and any associated symptoms will be
sent via WiFi or cellular network transmission to the
AliveCor® cloud. A login will occur daily to the
password-protected study database that will be stored
on the AliveCor® cloud in order to review and interpret
all ECG strips transmitted during the previous 24 h. Any
clinically significant arrhythmias, including AF or other
arrhythmias, detected during the daily review of ECGs
over the 6-month period will be immediately sent to the
provider caring for the participant. The study team will
ensure the provider has received the transmission, is
aware of any ECG abnormalities, and will then be
responsible for communicating such findings.
Smartphone
The study is innovative in its use of mHealth and widely
available smartphone technology, which allows rapid
two-way communication between patients and health-
care providers, rather than waiting for office or clinic
visits that delay care. An FDA-approved smartphone
technology is being used, the AliveCor® Mobile ECG to
capture and send ECG data via WiFi or cellular network
for immediate interpretation. Transmission of a normal
ECG while a patient is experiencing a symptom with
multiple underlying diagnoses impacts immediate triage
and treatment of the symptom. The AliveCor® technol-
ogy allows clinicians to correlate symptoms with heart
rhythms.
Unlike previous ECG technology, the AliveCor®
Mobile ECG is not worn, so it eliminates the need for
adhesive ECG electrodes and skin patches placed on the
chest and does not require complicated changing of
leads by the subject. This is a significant improvement
from previously available technology. The use of tailored
cardiac BAM text messaging sent to an individual’s
smartphone to improve AF awareness and knowledge, as
well as self-management of pre-existing chronic cardio-
vascular conditions associated with AF will be simultan-
eously evaluated.
Behavior Altering Motivational (BAM) text messaging
BAM one-way text messages are sent to the intervention
participant three times per week and pertain to their AF,
as well as two underlying cardiovascular risk factors of
the patient’s choosing (weight management, physical ac-
tivity, hypertension, heart failure, diabetes, etc.). Starting
on the day of enrollment, intervention participants will
receive text messages every Wednesday related to AF
management, as well as a message on Monday related to
risk factor one and a message on Friday related to risk
factor two. BAM text messages will be systematically se-
lected from a bank of text messages developed through
collaboration by the study team and an expert interdis-
ciplinary panel from the American Heart Association.
All messages are available in English and Spanish ac-
cording to participant preference.
Control group (usual care)
Participants randomized to usual care will continue their
guideline-directed clinical management and follow-up as
determined by their providers’ interpretation of the 2014
ACC/AHA/HRS Guideline for the Management of
Patients with Atrial Fibrillation [9].
Study end-points
The primary endpoint is detection of recurrence of AF.
Secondary endpoints include treatment changes as a
result of early detection of AF recurrence, study ques-
tionnaire scores at baseline and six months, including
QoL, QALYs, and improvement in cardiovascular mea-
sures (e.g., blood pressure, glucose levels) and AF know-
ledge from baseline to 6 months. Outcome assessors will
be blinded to group allocation.
Statistical analysis
We will define and calculate recurrent AF detection rate
as the ratio of the number of recurrent AF episodes to
Fig. 2 AliveCor™ Heart Monitor attached to an iPhone®
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the number of person-months of follow-ups. We will
compare the difference in recurrent AF detection rate
over the six-month study period between the control
group and the iHEART intervention group. Analysis of
the potential moderating effects of demographic factors
(e.g., age, gender, etc.) as well as the difference between
the groups will be performed using multivariate Poisson
regression.
We will compare the time-to-treatment between the
iHEART intervention group and the control group with
the application of survival analysis methods. For those
who are treated for recurrent AF, the time-to-treatment
is the time from beginning of study to the time of treat-
ment. Those who are not treated for recurrent AF will
be censored at the end of the sixth month, or the time
of death should a subject die before the sixth month.
We will apply the Cox proportional hazard model to
examine and test the difference in the time-to-treatment
between the intervention group and control group, with
the adjustment for other potential confounders (e.g., age,
gender). QALYs are calculated as follows: for each
month of life lived at an EQ-5D index of x, the QALYs
will be x/12 = 0.0833x years. We will calculate QALYs
during the 6-month study period for all participants by
summarizing QALYs from baseline through sixth month.
We will compare QALYs between the iHEART interven-
tion group and the control group using a two-tailed
independent sample t-test. To adjust for potential con-
founders (e.g., age, gender), multivariate linear regression
models will be used. Additionally, we will compare
change of QoL and symptoms of AF scores (AFEQT,
AFKS, EQ5D and CCS-SAF scales, etc.) from baseline to
6 months between the two groups and between those
with and without AF using linear mixed models (growth
model).
Discussion
This article describes the development and implementa-
tion of iHEART, a randomized controlled trial focusing
on the potential for more timely detection and treatment
of AF by actively engaging patients in their cardiac care.
Occurrence rates of AF after treatment with an electrical
or pharmacological cardioversion and/or radiofrequency
ablation to restore a normal sinus rhythm remain high
and can result in serious adverse cardiac outcomes if AF
remains undetected and untreated. In fact, this RCT
responds directly to a call to explore mHealth as a tool
for stroke prevention secondary to paroxysmal AF [13].
This protocol aims to capitalize on the AliveCor® Mobile
ECG’s documented ability to detect recurrent AF by for-
warding abnormal ECG transmissions to the participant’s
healthcare practitioner in real-time. Any resulting changes
in clinical management, such as medication adjustments
or procedures (i.e., repeat cardioversions, ablations, etc.),
will be captured and compared with the mechanism for
detection of AF and the clinical management in the usual
care group. Our trial is currently recruiting patients whose
AF has been previously treated with ablation, as well as
any other intervention including electrical and pharma-
ceutical cardioversion with a documented return to nor-
mal sinus rhythm. Participants transmit ECGs daily, and
more frequently if they are experiencing cardiac symp-
toms that may indicate AF, leading to an unprecedented
number of data points. We anticipate approximately
30,000 ECG transmissions from the intervention arm.
Unique to this protocol is the exploration of the im-
pact of text messaging on participant knowledge of AF
and behavior modification of associated cardiac risk
factors, such as hypertension, diabetes and heart failure.
The iHEART text messages were developed in conjunc-
tion with an expert interdisciplinary panel from the
American Heart Association and are available to partici-
pants in English or Spanish. The utility of text messaging
in reducing or preventing illness through self-
management and behavior alteration may reduce the
burden of AF and improve participants’ quality of life
and quality-adjusted life years. Utilizing an approach
where individuals can visually capture and see their real
time ECG may prove successful in improving AF detec-
tion through self-management.
Real time ECG transmission in the setting of multiple
cardiac diagnoses may effectively guide treatment in the
ambulatory setting preventing unnecessary visits and
associated healthcare utilization. For example, a patient
experiencing symptoms with multiple underlying diag-
noses who transmits a normal ECG can be ruled out for
recurrent AF and instead be treated accordingly. Muh-
lestein and colleagues concluded the AliveCor® Mobile
ECG is an adequate determinate of STEMI when com-
pared to 12 Lead ECGs at the time of presentation [14].
Also, the AliveCor® Mobile ECG’s ability to accurately
capture arrhythmias in the pediatric population has been
confirmed by the SPEAR Trial, [15] as well as Ferdman
et al. who used AliveCor® Mobile ECG to diagnose cases
of pediatric supraventricular tachycardia [16]. While
Muhlestein and colleagues did successfully monitor the
QTc interval for AF patients treated with dofetilide using
the AliveCor® Mobile ECG, [17] and Tarakji’s iTRANS-
MIT study [18] concluded the AliveCor® Mobile ECG
was an accurate alternative for detection of AF recurrence
after ablation among 60 participants, the evaluation of the
usefulness of the AliveCor® Mobile ECG in combination
with the Kardia application in the setting of AF has been
limited thus far. The silent nature of AF often leads to a
gross underdetection of recurrence [19]. Our study’s
innovative design and implementation of this technol-
ogy has the potential to address this issue among urban
communities.
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Bloss et al. found no difference in overall healthcare
utilization over a 6 month period among persons with
AF utilizing the AliveCor® application, however, their AF
arm required participants to transmit an ECG only when
symptomatic resulting in a mean of 57 transmissions per
participant [20]. Their study did not include a mechan-
ism for capturing silent episodes of AF, unlike our RCT,
which requires daily transmissions regardless of
symptoms.
Conclusions
If the aims of this study are achieved, we believe this
may alter existing guidelines for how ECG monitoring
and patient education are approached, as well as lay the
foundation for using mHealth interventions aimed at
improving health promotion, QoL and disease preven-
tion. The potential application of this project extends to
using mHealth for ECG monitoring to other under-
served, geographically diverse populations, as well as in
other fields of personalized healthcare. The utility of
mHealth in public health programs aimed at preventing
illness through self-management of behavior and treat-
ment of other chronic diseases known to be associated
with AF, such as heart failure, may improve healthcare
outcomes in the future.
Trial status
The study protocol and amendments were approved by
the Columbia University Human Research Protection
Office prior to the start of the study (IRB-AAAO2555).
The trial is also registered at www.clinicaltrials.gov
(NCT02731326). The study is currently ongoing, having
recently entered its second year of enrollment.
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